Cargando…

SARS-CoV-2 vaccine-associated subacute thyroiditis

PURPOSE: With coronavirus disease 2019 (COVID-19), subacute thyroiditis (SAT) cases are on the rise all over the world. COVID-19 vaccine-associated SAT cases have also been reported. In this article, we present our data on 11 vaccine-associated SAT cases. METHODS: Eleven patients were included in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yorulmaz, G., Sahin Tekin, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857746/
https://www.ncbi.nlm.nih.gov/pubmed/35182366
http://dx.doi.org/10.1007/s40618-022-01767-w
_version_ 1784654104968036352
author Yorulmaz, G.
Sahin Tekin, M.
author_facet Yorulmaz, G.
Sahin Tekin, M.
author_sort Yorulmaz, G.
collection PubMed
description PURPOSE: With coronavirus disease 2019 (COVID-19), subacute thyroiditis (SAT) cases are on the rise all over the world. COVID-19 vaccine-associated SAT cases have also been reported. In this article, we present our data on 11 vaccine-associated SAT cases. METHODS: Eleven patients were included in the study. Type of the vaccines patients received, time to the occurrence of SAT after vaccination, symptoms and laboratory findings, treatment given, and response to treatment were evaluated. RESULTS: The age of patients ranged from 26 to 73. Four of the patients were males, and seven were females. Symptoms of six patients were seen after BNT162b2 Pfizer/BioNTech COVID-19 mRNA vaccine®, and four of them after Coronavac inactivated SARS-CoV-2 vaccine®. In one patient, SAT developed after the first dose of BNT162b2, administered after two doses of Coronavac. The average time to the onset of symptoms was 22 days (15–37) after vaccination. CONCLUSIONS: The fact that both whole virus containing and genetic material containing vaccines cause SAT suggests that the trigger may be viral proteins rather than the whole viral particle. Although corticosteroids are commonly preferred in published vaccine-associated SAT cases, we preferred nonsteroidal anti-inflammatory therapy in our patients for sufficient vaccine antibody response. There is not enough information about whether patients who develop SAT can be revaccinated safely considering the ongoing pandemic. Further research is needed for a conclusion in the treatment and revaccination of these patients.
format Online
Article
Text
id pubmed-8857746
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88577462022-02-22 SARS-CoV-2 vaccine-associated subacute thyroiditis Yorulmaz, G. Sahin Tekin, M. J Endocrinol Invest Original Article PURPOSE: With coronavirus disease 2019 (COVID-19), subacute thyroiditis (SAT) cases are on the rise all over the world. COVID-19 vaccine-associated SAT cases have also been reported. In this article, we present our data on 11 vaccine-associated SAT cases. METHODS: Eleven patients were included in the study. Type of the vaccines patients received, time to the occurrence of SAT after vaccination, symptoms and laboratory findings, treatment given, and response to treatment were evaluated. RESULTS: The age of patients ranged from 26 to 73. Four of the patients were males, and seven were females. Symptoms of six patients were seen after BNT162b2 Pfizer/BioNTech COVID-19 mRNA vaccine®, and four of them after Coronavac inactivated SARS-CoV-2 vaccine®. In one patient, SAT developed after the first dose of BNT162b2, administered after two doses of Coronavac. The average time to the onset of symptoms was 22 days (15–37) after vaccination. CONCLUSIONS: The fact that both whole virus containing and genetic material containing vaccines cause SAT suggests that the trigger may be viral proteins rather than the whole viral particle. Although corticosteroids are commonly preferred in published vaccine-associated SAT cases, we preferred nonsteroidal anti-inflammatory therapy in our patients for sufficient vaccine antibody response. There is not enough information about whether patients who develop SAT can be revaccinated safely considering the ongoing pandemic. Further research is needed for a conclusion in the treatment and revaccination of these patients. Springer International Publishing 2022-02-19 2022 /pmc/articles/PMC8857746/ /pubmed/35182366 http://dx.doi.org/10.1007/s40618-022-01767-w Text en © Italian Society of Endocrinology (SIE) 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Yorulmaz, G.
Sahin Tekin, M.
SARS-CoV-2 vaccine-associated subacute thyroiditis
title SARS-CoV-2 vaccine-associated subacute thyroiditis
title_full SARS-CoV-2 vaccine-associated subacute thyroiditis
title_fullStr SARS-CoV-2 vaccine-associated subacute thyroiditis
title_full_unstemmed SARS-CoV-2 vaccine-associated subacute thyroiditis
title_short SARS-CoV-2 vaccine-associated subacute thyroiditis
title_sort sars-cov-2 vaccine-associated subacute thyroiditis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857746/
https://www.ncbi.nlm.nih.gov/pubmed/35182366
http://dx.doi.org/10.1007/s40618-022-01767-w
work_keys_str_mv AT yorulmazg sarscov2vaccineassociatedsubacutethyroiditis
AT sahintekinm sarscov2vaccineassociatedsubacutethyroiditis